Fact Sheet/Brochure

Provides pharmacists with information about prescription opioid use in the United States, the role of pharmacists as part of the pain management team and in preventing opioid use disorder, and communication with patients.

Provides information about opioid dependence, buprenorphine, DATA 2000, and ways to find treatment.

Supports face-to-face training to review results from research conducted by the NIDA CTN comparing detoxification with buprenorphine versus clonidine. Provides instruction for implementing this protocol in treatment settings, including methods of evaluation and induction, the taper schedule, and use of ancillary medications during treatment.

Gives patients information on buprenorphine and MAT for opioid addiction. Describes addiction and withdrawal and how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.

Highlights the findings of the NIDA Clinical Trials Network study that compared longer term versus short-term buprenorphine/naloxone treatment in an outpatient setting. Examines opioid use, treatment with buprenorphine, and further implications for young adults with opioid addiction.

Gives patients information on naltrexone and MAT for opioid addiction. Describes addiction and withdrawal and how naltrexone works, its proper use, its side effects, and how it fits with counseling in the recovery process.

Provides an overview of science-based solutions for treating patients with opioid addiction.

Uses graphics and a description of the pharmacology to explain buprenorphine in lay terms.

Provides facts about the benefits of using PDMPs for prescribers, pharmacists, patients, and regulatory and law enforcement agencies.

Provides information for pregnant women about how taking methadone or buprenorphine may affect delivery, breastfeeding, and newborn infants.